738 results on '"Geavlete B"'
Search Results
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
- Author
-
Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.
- Published
- 2019
- Full Text
- View/download PDF
3. High-Risk Non-Muscle Invasive Bladder Cancer associated with Prostate Cancer
- Author
-
Geavlete, B., primary, Bulai, C., additional, Ene, C., additional, Ene, A., additional, Mares, C., additional, Georgescu, D., additional, Geavlete, P., additional, and Popescu, R., additional
- Published
- 2023
- Full Text
- View/download PDF
4. The long term 5 years’ oncologic impact of narrow band imaging – en bloc bipolar plasma resection hybrid approach versus the standard diagnostic and treatment protocol – A matched-paired, index-control cohort long-term clinical comparison
- Author
-
Geavlete, B., primary, Ene, C., additional, Bulai, C., additional, Popescu, R., additional, Mares, C., additional, and Geavlete, P., additional
- Published
- 2023
- Full Text
- View/download PDF
5. NBI-assisted Digital Flexible Ureteroscopy in the Management of Upper Tract Urothelial Carcinoma
- Author
-
Geavlete, B., primary, Iordache, V.F., additional, Ene, C.V., additional, Bulai, C.A., additional, Popescu, R.I., additional, and Mares, C., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Semirigid
- Author
-
MARES, C., primary, GEAVLETE, P., additional, ENE, C., additional, IORDACHE, V., additional, and GEAVLETE, B., additional
- Published
- 2023
- Full Text
- View/download PDF
7. The Management of Reno-Ureteral Lithiasis – from Emergency Presentation to Definitive Treatment
- Author
-
GEAVLETE, P., PLESUVESCU, A., STANESCU, F., ENE, C., POPESCU, R., IORDACHE, V., and GEAVLETE, B.
- Subjects
Review - Abstract
Introduction: The aim of our study was to retrospectively evaluate the stone-free rate after the second intervention for every performed procedure (semirigid ureteroscopy, flexible ureteroscopy, semirigid plus flexible ureteroscopy and percutaneous nephrolithotomy). Materials and methods: A total of 149 patients, who came to the emergency room of “Saint John” Emergency Clinical Hospital, Bucharest, Romania, with acute renal pathology suggesting the presence of renal and/or ureteral lithiasis confirmed by imagining (x-ray, ultrasonography or computer tomography), were included in this retrospective study, which was conducted between September 2021 and September 2022. All selected patients had an indication of emergency surgical intervention that consisted of a double-J stent mounting. We analyzed the stone-free rate after the secondary intervention, which was one of the following procedures: semirigid ureteroscopy, flexible ureteroscopy, combined semirigid and flexible ureteroscopy (F-URS), and percutaneous nephrolithotomy (PCNL). Patients came back for the secondary intervention and were reevaluated using imaging techniques. Results:Endoscopic procedures were performed by 14 surgeons over a time period of two to six weeks after the initial stenting procedure. Encrusted stents were encountered in four cases and in five cases the patients were admitted with obstruction of previously inserted stents. From the total of 149 patients, 68 (45,6%) subjects underwent semirigid ureteroscopy, with a stone-free rate of 86% (59 cases), 32 (21,4%) F-URS, with a stone-free rate of 90,6% (30 cases), 41 (27,5%) combined flexible and semirigid ureteroscopy, with a stone-free rate of 90,24% (37 cases), and eight (5,3%) patients received PCNL, with a stone-free rate of 75% (six cases). Overall stone-free rate for all procedures was 90,06%. The mean operative time was 23 minutes. No major incidents or complications occurred during the procedures. Conclusion:The emergency pre-stenting before the definitive treatment of reno-ureteral lithiasis is a safe procedure. Flexible ureteroscopy was the most successful secondary intervention, with the highest rate of achieving stone-free status.
- Published
- 2023
8. The Influence of SARS-CoV-2 on Minimally Invasive Therapeutic Approach for Benign Prostatic Hyperplasia
- Author
-
BALACESCU, S, POPESCU, R, GEORGESCU, D, ENE, C, MIRCIULESCU, V, MOLDOVEANU, C, BULAI, C, MILITARE, A, PUNGA, A, ALEXANDRESCU, E, GEAVLETE, P, and GEAVLETE, B
- Subjects
Original Paper - Abstract
Introduction: The COVID-19 pandemic definitely changed the management of patients with benign prostatic hyperplasia (BPH). This study followed the modalities of treatments in patients with BPH associated with SARS-CoV-2 attending the Urology Clinic of “Sf. Ioan” Emergency Clinical Hospital, Bucharest, Romania. Material and methods:The present study included 81 patients (mean age 63.2 years, age range 55–87 years) with SARS-CoV-2 and BPH who were admitted to our Urology Department between January 2021 and January 2022. The diagnosis of SARS-CoV-2 was based on the PCR test and that of BPH by using the diagnostic triad consisting of digital rectal examination, PSA, free PSA and ultrasound examination. It should be noted that some of the hospitalized patients were following treatment with alpha blockers and/or 5-alpha-reductase inhibitors at the time of admission. Results:Out of the 81 hospitalized cases, 13 required emergency endoscopic intervention under spinal anaesthesia (TURP or TURisP) for haemostasis because those patients presented with persistent haematuria which did not respond to conservative treatment. A number of 17 cases showed acute urinary retention during hospitalization and a urethrovesical catheter was fitted and will be re-evaluated urologically after the COVID episode. Of the remaining 51 subjects with BPH, 17 already had chronic urinary retention on admission, with urethrovesical probe present, 13 cases began during hospitalization with alpha-blocker treatment associated with 5-alpha-reductase inhibitors; meanwhile, there were no urological interventions to modify the treatment regimen in the remaining 21 patients, who were strictly managed on the side of COVID-19 infection. Conclusion:There was no clear influence of the evolution of patients with BPH due to SARS-CoV-2 pathology, and the general management trend was to delay chronic cases until the time of viral infection remission.
- Published
- 2022
9. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer
- Author
-
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A
- Subjects
Treatment ,Consensus ,Follow-up ,education ,Bladder cancer ,Diagnosis ,Consensu ,Delphi ,Diagnosi - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and
- Published
- 2020
10. Narrow Band Imaging (NBI) : mise au point sur la technique et expérience initiale pour les tumeurs de la voie excrétrice urinaire supérieure
- Author
-
Meyer, F., Al Qahtani, S., Gil-Diez de Medina, S., Geavlete, B., Thomas, A., and Traxer, O.
- Published
- 2011
- Full Text
- View/download PDF
11. Première expérience avec le nouveau superpulsed laser (SOLTIVE)
- Author
-
Geavlete, B., primary, Iordache, V., additional, and Geavlete, P., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Première expérience avec le nouvel urétéroscope souple à usage unique–sufurs, PU 3033A, 7,5 FR
- Author
-
Geavlete, B., primary, Iordache, V., additional, and Geavlete, P., additional
- Published
- 2021
- Full Text
- View/download PDF
13. Is cystoscopic sphincter evaluation a reliable witness before continence surgery? A prospective, blinded, real life, single centre study
- Author
-
Tutolo, M., primary, Rosiello, G., additional, Cristodoro, M., additional, Bruyneel, L., additional, De Ridder, D., additional, Beels, E., additional, Heesakkers, J., additional, Everaert, K., additional, Kasyan, G., additional, Van Bruwaene, S., additional, Geavlete, B., additional, Ammirati, E., additional, Barletta, F.M., additional, Cannoletta, D., additional, Scuderi, S., additional, Salonia, A., additional, Briganti, A., additional, and Van der Aa, F., additional
- Published
- 2021
- Full Text
- View/download PDF
14. P243 - NBI-assisted Digital Flexible Ureteroscopy in the Management of Upper Tract Urothelial Carcinoma
- Author
-
Geavlete, B., Iordache, V.F., Ene, C.V., Bulai, C.A., Popescu, R.I., and Mares, C.
- Published
- 2023
- Full Text
- View/download PDF
15. P252 - The long term 5 years’ oncologic impact of narrow band imaging – en bloc bipolar plasma resection hybrid approach versus the standard diagnostic and treatment protocol – A matched-paired, index-control cohort long-term clinical comparison
- Author
-
Geavlete, B., Ene, C., Bulai, C., Popescu, R., Mares, C., and Geavlete, P.
- Published
- 2023
- Full Text
- View/download PDF
16. P202 - High-Risk Non-Muscle Invasive Bladder Cancer associated with Prostate Cancer
- Author
-
Geavlete, B., Bulai, C., Ene, C., Ene, A., Mares, C., Georgescu, D., Geavlete, P., and Popescu, R.
- Published
- 2023
- Full Text
- View/download PDF
17. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
- Author
-
Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.
- Abstract
The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology
- Published
- 2020
18. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
- Author
-
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.
- Subjects
Consensus ,Follow-up ,education ,Bladder cancer ,Diagnosis ,Treatment ,Delphi - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
- Published
- 2020
19. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees
- Author
-
Witjes, JA, Babjuk, M, Bellmunt, J, Bruins, HM, De Reijke, TM, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmueller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Mueller, A-C, Mueller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, M, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimae, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Horwich, A, Witjes, JA, Babjuk, M, Bellmunt, J, Bruins, HM, De Reijke, TM, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmueller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Mueller, A-C, Mueller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, M, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimae, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A
- Abstract
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus stateme
- Published
- 2020
20. Bipolar plasma vaporization and NBI in large non-muscle invasive bladder tumors - better than the standard approach: B5
- Author
-
Geavlete, B, Multescu, R, Stanescu, F, Georgescu, D, Jecu, M, and Geavlete, P
- Published
- 2011
21. La résection bipolaire en bloc au plasma des tumeurs vésicales non invasives de la musculaire, guidée par NBI, face à la résection monopolaire standard – Profil oncologique supérieur à long terme pour une technique hybride
- Author
-
Geavlete, B., primary, Ene, C., additional, Bulai, C., additional, Ene, A., additional, Moldoveanu, C., additional, and Geavlete, P., additional
- Published
- 2020
- Full Text
- View/download PDF
22. Le test du temps pour les progrès technologiques dans la chirurgie bipolaire de la prostate – Comparaison dans une manière prospective, randomisée, de la vaporisation bipolaire de la prostate au plasma en mode continue, à la vaporisation standard et à la résection monopolaire, ainsi qu’une parallèle entre la vaporisation au plasma, la résection, l’énucléation bipolaire et la prostatectomie ouverte
- Author
-
Geavlete, B., primary, Ene, C., additional, Bulai, C., additional, Ene, A., additional, Moldoveanu, C., additional, and Geavlete, P., additional
- Published
- 2020
- Full Text
- View/download PDF
23. Innovative Technique in Non-muscle Invasive Bladder Cancer - Bipolar Plasma Vaporization, a Reliable Approach?: 134
- Author
-
Geavlete, P, Geavlete, B, Jecu, M, Multescu, R, Georgescu, D, and Dragutescu, M
- Published
- 2010
24. High-risk Non-muscle Invasive Bladder Cancer - “The Real Deal” for Blue Light Cystoscopy and TURBT?: 126
- Author
-
Geavlete, P, Geavlete, B, Jecu, M, Multescu, R, Georgescu, D, and Dragutescu, M
- Published
- 2010
25. Erectile dysfunction post-radical prostatectomy – a challenge for both patient and physician
- Author
-
Bratu, O, Oprea, I, Marcu, D, Spinu, D, Niculae, A, Geavlete, B, and Mischianu, D
- Subjects
Male ,Prostatectomy ,erectile dysfunction ,Physicians ,phosphodiesterase 5 inhibitors ,Humans ,Reviews ,penile implant prosthesis ,Alprostadil ,Penile Prosthesis ,intraurethral suppositories ,vacuum erectile devices - Abstract
Post-radical prostatectomy erectile dysfunction (post RP ED) is a major postoperative complication with a great impact on the quality of life of the patients. Until present, no proper algorithm or guideline based on the clinical trials has been established for the management of post RP ED. According to literature, it is better to initiate a penile rehabilitation program as soon as possible after surgery than doing nothing, in order to prevent and limit the postoperative local hypoxygenation and fibrosis. The results of numerous clinical trials regarding the effectiveness of the phosphodiesterase 5 inhibitors therapy on post RP ED have made them the gold standard treatment. Encouraging results have been achieved in studies with vacuum erectile devices, intraurethral suppositories with alprostadil and intracavernosal injections, but due to their side effects, especially in the cases of intracavernosal injections and intraurethral suppositories, their clinical use was limited therefore making them a second line option for the post RP ED treatment. What should not be forgotten is that penile implant prosthesis has proven very effective, numerous studies confirming high rates of satisfaction for both patients and partners.
- Published
- 2017
26. Urinary Tract Infections in the COVID-19 Era -- A Multicenter Experience.
- Author
-
Ene C., Geavlete P., Mirciulescu V., Moldoveanu C., Bulai C., Bălăcescu S., Militaru A., Pungă A., Georgescu D., Popescu R., Ene C. D., and Geavlete B.
- Subjects
COVID-19 pandemic ,URINARY tract infections ,COVID-19 ,SARS-CoV-2 ,ESCHERICHIA coli ,ESCHERICHIA coli diseases - Abstract
Introduction and Objectives. Post-operative urinary tract infections continue to be a reality in emergency urology wards, even as the number of cases due to the SARS-COV2 pandemic is reduced. The purpose of this study is to determine the type of urinary tract infection most common in our clinic, as well as the possible procedures after which it begins. Materials and Methods. The study is retrospective, being conducted between January 2021 and January 2022 on a number of 534 patients, of which 256 were operated. Of the 534 hospitalized patients, 128 had a positive SARS-COV2 test at hospitalization. A percentage of (65) 25.4% of operated patients reported postoperative urinary tract infections. The diagnosis was considered postoperative if the patients showed positive results regarding the presence of germs in the urine sample in the first 15 days after the medical intervention compared to the "sterile" urine sample before the procedure. Results. The most common type of postoperative urinary tract infection is with: Escherichia Coli bacterium in 39.5% (211) cases, followed by Klebsiella pneumoniae in 24.1% (129 cases), Proteus mirabilis in 17.6% (94 cases), Enterococcus faecalis in a percentage of 10.8% (58 cases) and Pseudomonas aeruginosa in a number of 7.8% (42 cases). Of the patients diagnosed with SARS-COV2, a total of 33 cases required urological interventions, while 29 cases required only conservative treatment. The prevalence of germs in operated patients was 14 cases (42.4%) with E. coli infection, 13 cases (39.4%) with Klebsiella infection and 6 cases (18.2%) with Proteus infection. Of those who required conservative treatment, 19 cases (65.5%) had E. coli infection and 10 cases (34.5%) with Klebsiella. The rate of postoperative urinary tract infections was higher after endoscopic procedures (70.7 %%) compared to classical surgical ones (29.3%). Of the cases with SARS-COV 2 that presented associated urinary tract infections, a number of 17 (27.4%) showed severe clinical evolution with prolonged hospitalization or exitus. Conclusions. Urinary tract infections remain a current challenge especially in the COVID-19 era, when along with viral evolution, they can worsen the prognosis of patients, which leads to higher morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
27. Minimally Invasive Therapeutic Approach for Benign Prostatic Hyperplasia under the Impact of the SARS-COV2 Pandemic.
- Author
-
Bălăcescu S., Georgescu D., Ene C., Mirciulescu V., Moldoveanu C., Bulai C., Militaru A., Pungă A., Alexandrescu E., Geavlete P., and Geavlete B.
- Subjects
BENIGN prostatic hyperplasia ,RETENTION of urine ,THERAPEUTICS ,SARS-CoV-2 ,DIGITAL rectal examination ,COVID-19 - Abstract
Introduction and Objectives. The COVID-19 pandemic definitely changed the management of patients with benign prostatic hyperplasia. This study followed the modalities of treatments in patients with benign prostatic hyperplasia associated with SARS-COV2 in the Urology Clinic of St. John's Emergency Clinical Hospital. Materials and Methods. The study included a number of 78 patients, with a mean age of 63.2 years (55-87) who presented with SARS-COV2 and BPH and who were admitted to our Urology Department between January 2021 and January 2022. The diagnosis of SARS-COV2 was made based on the PCR test, and that of BPH, using the diagnostic triad: digital rectal examination, PSA, freePSA and ultrasound examination. It should be noted that some of the hospitalized patients were already being treated with alpha blockers and/or 5 alpha reductase inhibitors at the time of admission. Results. Out of the 78 hospitalized cases, 11 required emergency endoscopic intervention under spinal anesthesia (TURP or TURisP) for haemostasis, the patients presenting with persistent hematuria, which did not respond to conservative treatment. A number of 16 cases showed acute urinary retention during hospitalization and a urethrovesical catheter was fitted and will be re-evaluated urologically after the COVID episode. Of the remaining 51 cases of BPH, 17 already had chronic urinary retention on admission, with urethrovesical probe present, 13 cases began during hospitalization with alpha blocker treatment associated with 5 alpha reductase inhibitors, meanwhile in the remaining 21 cases there were no urological interventions to modify the treatment regimen, these cases being managed strictly on the side of COVID-19 infection. Conclusions. There was no clear influence of the evolution of patients with benign prostatic hyperplasia due to SARS-COV2 pathology, and the general management trend was to delay chronic cases until the time of remission of viral infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
28. COVID-19 Pandemic and Hematuria Patients - The Perspective of an Emergency Urological COVID Care Unit.
- Author
-
Militaru, A., Bulai, C., Ene, C., Punga, A., Geavlete, P., Georgescu, D., and Geavlete, B.
- Subjects
COVID-19 treatment ,COVID-19 pandemic ,HEMATURIA ,BLADDER stones ,INTERSTITIAL cystitis ,BLADDER cancer ,TRANSITIONAL cell carcinoma - Abstract
Introduction and Objectives. Gross hematuria is one of the urological emergencies that require immediate assessment. Our retrospective study aimed to describe the demographic and clinical characteristics of patients with hematuria and SARS-CoV-2 infection treated in a urological emergency COVID care unit and compare them to pre-COVID-19 outcomes of the same duration. Materials and Methods. Over ten months, 55 patients with hematuria and SARS-CoV-2 infection were enrolled in the study and compared to pre-COVID-19 outcomes of similar duration. Data analyzed included patient age and gender, the etiology of hematuria, treatment applied, and follow-up time. Results. According to the analysis, there were 36 men (65.5%) and 19 women (34.5%), with an average age of 64.43 years (45 - 86). In men, 15 cases (41.7%) of hematuria were related to bladder tumors, eight cases (22.2%) to prostate adenocarcinomas, five cases (13.9%) to bladder stones, five cases (13.9%) to upper tract urothelial carcinomas, and three cases (8.3%) were related to large prostate adenoma. Among women, hematuria was associated with bladder tumors in 12 cases (63.2%) and with radiation cystitis in seven cases (36.8%). Conservative treatment was successfully applied in 17 cases (30.9%) and surgical treatment was necessary for 38 patients. (61.9%). As for SARS-CoV-2 infection, 40 patients (72.7%) showed a mild to moderate form of COVID-19, 12 patients (21.8%) had a severe course of the disease, with 3 cases (5.5%) resulting in death. All data were compared with pre-pandemic outcomes of similar duration. Conclusions. Hematuria associated with SARS-CoV-2 infection impairs a patient's prognosis. With SARS-CoV-2 infection, hematuria surgery is more challenging to perform. [ABSTRACT FROM AUTHOR]
- Published
- 2022
29. A Review on the Impact of Bisphenol A on the Male Genitourinary System.
- Author
-
Mareș, C., Geavlete, P., Popescu, R.-I., and Geavlete, B.
- Subjects
BISPHENOL A ,POLLUTANTS ,ENDOCRINE system ,HORMONE receptors ,KIDNEY physiology - Abstract
Bisphenol A (BPA) is a widespread environmental pollutant caused mainly by the production, use, or disposal of plastics and the degradation of industrial plastic-related wastes. Growing data from studies on humans, lab animals, and wildlife supports the idea that BPA has a detrimental effect on male renal and reproductive function by disrupting the endocrine system. We reviewed the literature for a better understanding of the negative effects of BPA exposure, focusing on the impacts of BPA on kidney, prostate, and testicular health. Current data suggest an impaired renal function in individuals with chronic BPA exposure and raise an important issue regarding the presence of this plastic chemical in the dialysis product. The method by that BPA affects prostate tissue is intricated. The frequency of precancerous or cancerous lesions, such as a PIN or even prostate cancer, is rising among elderly males who have had their stem cells reprogrammed by estrogen-like action. Various studies revealed that early exposure to BPA could cause the prostate to develop several different epigenetic modifications, leading to neoplastic alterations of prostate cells. The idea that BPA has an endocrine-disrupting effect and adversely affects male reproductive function is supported by mounting data from studies on laboratory animals, wildlife, and people. By altering the production, expression, and activity of specific receptors for hormones (such as LH and FSH, androgen, and estrogen), BPA has an impact on the hypothalamic-pituitary-testicular axis (ER, AR). Sperm parameters are changed by these effects. By blocking antioxidant enzymes and promoting lipid peroxidation, BPA also causes oxidative stress in the testis and epididymis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
30. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
- Author
-
Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.
- Subjects
education - Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology
- Published
- 2019
31. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees
- Author
-
Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, Amir, Smeenk, R J, Smits, A, Stenzl, A, Thalmann, G N, Tombal, B, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Der Heijden, A G, Van Poppel, H, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Witjes, J A, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, Amir, Smeenk, R J, Smits, A, Stenzl, A, Thalmann, G N, Tombal, B, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Der Heijden, A G, Van Poppel, H, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Witjes, J A
- Abstract
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus sta
- Published
- 2019
- Full Text
- View/download PDF
32. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.
- Author
-
UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, J A, Van Der Heijden, A G, Smits, A, Stenzl, A, Thalmann, G N, Tombal, Bertrand, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Poppel, H, Sherif, A, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Smeenk, R J, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, J A, Van Der Heijden, A G, Smits, A, Stenzl, A, Thalmann, G N, Tombal, Bertrand, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Poppel, H, Sherif, A, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Smeenk, R J, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, and Sengupta, S
- Abstract
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus sta
- Published
- 2019
33. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
- Author
-
Cancer, Verpleegkundig Specialisten, MS Urologische Oncologie, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, R J, Smits, A, Stenzl, A, Thalmann, G N, Tombal, B, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Der Heijden, A G, Van Poppel, H, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, Witjes, J A, Cancer, Verpleegkundig Specialisten, MS Urologische Oncologie, Horwich, A, Babjuk, M, Bellmunt, J, Bruins, H M, Reijke, T M De, Santis, M De, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, M J, Shariat, S F, Kwast, T Van Der, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, P C, Bochner, B H, Bolla, M, Boormans, J L, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, B De, Blok, W De, De Visschere, P J L, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, J L, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, J J, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, D E, Hartmann, A, Hayne, D, Henry, A M, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, B A, Jones, R, Kamat, A M, Khoo, V, Kiltie, A E, Krege, S, Ladoire, S, Lara, P C, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, M Carmen, Moschini, M, Mostafid, H, Müller, A-C, Müller, C R, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, J R, Oldenburg, J, Osanto, S, Oyen, W J G, Pacheco-Figueiredo, L, Pappot, H, Patel, M I, Pieters, B R, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, J E, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, R J, Smits, A, Stenzl, A, Thalmann, G N, Tombal, B, Turkbey, B, Lauridsen, S Vahr, Valdagni, R, Van Der Heijden, A G, Van Poppel, H, Vartolomei, M D, Veskimäe, E, Vilaseca, A, Rivera, F A Vives, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Witjes, J A
- Published
- 2019
34. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort:under the auspices of the EAU and ESMO Guidelines Committees†
- Author
-
Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H. M., Reijke, T. M.De, Santis, M. De, Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M. J., Shariat, S. F., Kwast, T. Van Der, Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P. C., Bochner, B. H., Bolla, M., Boormans, J. L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., Bari, B. De, Blok, W. De, De Visschere, P. J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J. L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J. J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D. E., Hartmann, A., Hayne, D., Henry, A. M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B. A., Jones, R., Kamat, A. M., Khoo, V., Kiltie, A. E., Krege, S., Ladoire, S., Lara, P. C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Mir, M. Carmen, Moschini, M., Mostafid, H., Müller, A. C., Müller, C. R., N'Dow, J., Necchi, A., Neuzillet, Y., Oddens, J. R., Oldenburg, J., Osanto, S., Oyen, W. J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M. I., Pieters, B. R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J. E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R. J., Smits, A., Stenzl, A., Thalmann, G. N., Tombal, B., Turkbey, B., Lauridsen, S. Vahr, Valdagni, R., Van Der Heijden, A. G., Van Poppel, H., Vartolomei, M. D., Veskimäe, E., Vilaseca, A., Rivera, F. A.Vives, Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., Witjes, J. A., Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H. M., Reijke, T. M.De, Santis, M. De, Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M. J., Shariat, S. F., Kwast, T. Van Der, Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P. C., Bochner, B. H., Bolla, M., Boormans, J. L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., Bari, B. De, Blok, W. De, De Visschere, P. J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J. L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J. J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D. E., Hartmann, A., Hayne, D., Henry, A. M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B. A., Jones, R., Kamat, A. M., Khoo, V., Kiltie, A. E., Krege, S., Ladoire, S., Lara, P. C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Mir, M. Carmen, Moschini, M., Mostafid, H., Müller, A. C., Müller, C. R., N'Dow, J., Necchi, A., Neuzillet, Y., Oddens, J. R., Oldenburg, J., Osanto, S., Oyen, W. J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M. I., Pieters, B. R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J. E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R. J., Smits, A., Stenzl, A., Thalmann, G. N., Tombal, B., Turkbey, B., Lauridsen, S. Vahr, Valdagni, R., Van Der Heijden, A. G., Van Poppel, H., Vartolomei, M. D., Veskimäe, E., Vilaseca, A., Rivera, F. A.Vives, Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J. A.
- Abstract
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus
- Published
- 2019
35. Renal Subcapsular Abscess Management in a Young Patient without Comorbidities.
- Author
-
Vacaroiu, I., Geavlete, P., Multescu, R., Ene, C., Bulai, C., and Geavlete, B.
- Subjects
UROLOGICAL surgery ,ABSCESSES ,PATIENT monitoring ,ENGLISH literature - Abstract
Introduction and Objectives. Renal subcapsular abscess is a very rare entity that is defined by a suppurative process localized to a space between the renal capsule and the renal parenchyma. However, the pathogenesis and aetiology of this entity remain speculative. To our knowledge, only few cases have been reported in the English literature. Materials and Methods. We describe a 26-years old woman with renal subcapsular abscess where the imagery pleaded for an interventional procedure, while her clinical and biological status were more suitable for conservative management. The particularity of the cases consisted in a conservative management with good outcomes. We also performed research on the literature in order to find arguments pros and against our therapeutical decision. Results. Despite the definite diagnosis, the patient’s improved clinic and favourable evolution determined the decision to abstain from drainage, considering that this procedure could have a risk of complete compromise of left kidney. In agreement with the patient, it was decided to delay the surgical approach. We ensured this evolution through clinical, paraclinical and imaging evaluations - a CT re-evaluation 14 days after hospitalization, then only ultrasound evaluations, because we already had the CT-ECO correspondence and no other contrast administrations were justified. Conclusions. Although the renal abscess exceeded the 5 cm border, described in the literature as the limit from which surgery is performed, the favourable evolution of the patient, under double antibiotic therapy, decreased inflamma)tory syndrome, and good collaboration between the 2 specialists, nephrological and urological, together with the careful monitoring of the patient, saved the left kidney in a patient with pre-existing CKD and with a small right kidney (approx. 8 cm). [ABSTRACT FROM AUTHOR]
- Published
- 2021
36. Single-Use versus Conventional Reusable Flexible Ureteroscopes – An Evaluation of the Functional Parameters.
- Author
-
Bragaru, M., Ene, C., Geavlete, P., Multescu, R., Georgescu, D., and Geavlete, B.
- Subjects
URINARY calculi ,KIDNEY stones - Abstract
Introduction and Objectives. The purpose of single-use flexible ureteroscopes (su-fURS) was to overcome the main limitations of conventional reusable ureteroscopes in terms of maneuverability and of the maintenance. We aimed to perform a systematic literature review on available su-fURS performance versus conventional reusable fURS with a focus on clinical data. Materials and Methods. A systematic research using electronic database Pubmed was performed for studies evaluating single-use fURS and reusable fURS in the setting of urinary tract stone disease. Prospective assessments and case series studies were included. The goal of this review was to provide an overview of these single use and disposable flexible ureteroscopes and to examine and compare their capabilities (deflection, irrigation, optical properties). Results. We found 11 studies which met our inclusion criteria, where it was compared the single use fURS with reusable fURS. The studies about single-use ureteroscopes included data on LithoVue (Boston Scientific), The Uscope UE3022 (Pusen, Zhuhai, China), NeoFlex-Flexible, (Neoscope Inc San Jose, CA), 23 YC-FR-A (Shaogang). Reusable ureteroscopes studies included data about three models, two digital (Karl Storz Flex-XC and Olympus URF-Vo) and one fiber optic (Wolf-Cobra). There were not significant statistical differences concerning stone-free rate, procedure duration, functional capabilities between single-use fURS and reusable fURS. Conclusions. Single-use fURS demonstrate a comparable efficacy with reusable fURS in resolving renal lithiasis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
37. No Touch Technique in Ureteroscopic Treatment of Renal Stones.
- Author
-
Geavlete, B., Multescu, R., Cozma, C., and Geavlete, P.
- Subjects
KIDNEY stones ,URETEROSCOPY ,HOSPITAL admission & discharge - Abstract
Introduction and Objectives. Large meta-analyses demonstrated that wires and access sheaths (UAS) have their specific complications rate during and after flexible ureteroscopy (fURS). So, in selected cases, we applied no touch technique (NTT) by only visual insertion and progression of the flexible scope with intrarenal disintegration of the stones. Materials and Methods. A total of 288 patients with single pyelocaliceal stone (largest diameter between 11 and 29 mm) underwent fURS: 144 using the 12/14 Fr UAS (group 1) and 144 without UAS (Group 2). For NTT we used 4 types of ureteroscopes: Olympus URF-V2 (8.5 Fr) – 33 cases, Storz Flex X2 (8.4 Fr) – 60 cases, single-use PUSEN PU 3022 (9.5 Fr) – 37 cases and single-use PUSEN – PU 3033A (7.5 Fr) – 14 cases. For the group 1 patients we used the Olympus URF – V2 ureteroscope in 44 cases, the Storz Flex X2 in 58 cases, and the single-use PUSEN PU 3022 in 42 cases. We compared the operative time, hospitalization periods and complications. Clinical data and outcomes were compared between the 2 groups. Results. Successful access sheath insertion was 83.3% in Group 1 and successful ureteroscope insertion was 90.9% in Group 2. The average operative time was slightly higher in Group 1 vs. Group 2 (47 vs. 39 min.). SFRs were overall lower in the Group 2 (76.3% vs. 86.8%) at 1 month. At 3 months we didn’t find significant difference between these 2 Groups. Superficial mucosal ureteral wall lesions were found in 38.8% of the Group 1 and 4.1% in the Group 2. The average urinary tract infection rate was slightly higher in the Group 2 (11.1% vs 9%). Hospitalization periods were longer in Group 1 vs. Group 2 (21 vs. 29 hours). A special mention for single-use 7.5 Fr ureteroscope: the insertion was simple, we did not encounter any mucosal ureteral wall lesions, and all patients were discharged in the same day. Conclusions. Despite clear advantages of UAS using, there are a lot of disadvantages for the patient. Larger diameter UASs involve greater risk for ureteral wall injury. NTT seems to be very efficient and safe. The new Ureteroscope 7.5 Fr maximize surgical efficiency and minimize the complication rate in ureteroscopic treatment of renal stones. [ABSTRACT FROM AUTHOR]
- Published
- 2021
38. Influencing residual stone size and stone-free rate subsequent to flexible ureteroscopy – Evidence-based “means to an end” by combination potassium, magnesium citrate and pyridoxine within a prospective, randomized-controlled clinical trial
- Author
-
Geavlete, B., primary, Moldoveanu, C., additional, Ene, C., additional, Bulai, C., additional, Balan, G., additional, Ene, A., additional, Bloju, M., additional, and Geavlete, P., additional
- Published
- 2019
- Full Text
- View/download PDF
39. Two years follow-up of clinical comparison in high volume benign prostatic obstruction cases – bipolar plasma enucleation and open prostatectomy
- Author
-
Bulai, C., primary, Moldoveanu, C., additional, Stanescu, F., additional, Ene, C., additional, Balan, G., additional, Georgescu, D., additional, Mansour, M., additional, Geavlete, P., additional, and Geavlete, B., additional
- Published
- 2019
- Full Text
- View/download PDF
40. Septic complications in flexible ureteroscopic approach of pyelocaliceal stones
- Author
-
Multescu, D.R., primary, Stan, M., additional, Bucur, C., additional, Geavlete, B., additional, Georgescu, D., additional, and Geavlete, P., additional
- Published
- 2019
- Full Text
- View/download PDF
41. The role of NBI cystoscopy in the diagnostic of satellite tumors and false- positive lesions in patients with large non-invasive bladder tumors
- Author
-
Stanescu, F., primary, Georgescu, D., additional, Balan, G., additional, Moldoveanu, C., additional, Jecu, M., additional, Bucur, C.C., additional, Bulai, C., additional, Bragaru, M., additional, Asproiu, E., additional, Geavlete, P., additional, and Geavlete, B., additional
- Published
- 2019
- Full Text
- View/download PDF
42. Bipolar en bloc tumor resection versus standard monopolar TURBT in non-muscle invasive bladder cancer – a medium-term, prospective, randomized-controlled comparison
- Author
-
Geavlete, B., primary, Multescu, R., additional, Georgescu, D., additional, Moldoveanu, C., additional, Ene, C., additional, Bulai, C., additional, Balan, G., additional, Ene, A., additional, and Geavlete, P., additional
- Published
- 2019
- Full Text
- View/download PDF
43. NBI versus white light digital flexible ureteroscopy in transitional renal cell carcinoma – an evidence-based, prospective, pathology-blinded comparison
- Author
-
Geavlete, B., primary, Multescu, R., additional, Georgescu, D., additional, Moldoveanu, C., additional, Ene, C., additional, Bulai, C., additional, Balan, G., additional, Ene, A., additional, and Geavlete, P., additional
- Published
- 2019
- Full Text
- View/download PDF
44. SC148 - Is cystoscopic sphincter evaluation a reliable witness before continence surgery? A prospective, blinded, real life, single centre study
- Author
-
Tutolo, M., Rosiello, G., Cristodoro, M., Bruyneel, L., De Ridder, D., Beels, E., Heesakkers, J., Everaert, K., Kasyan, G., Van Bruwaene, S., Geavlete, B., Ammirati, E., Barletta, F.M., Cannoletta, D., Scuderi, S., Salonia, A., Briganti, A., and Van der Aa, F.
- Published
- 2021
- Full Text
- View/download PDF
45. Diagnostic developments and treatment strategies in the endoscopic management of upper-tract urothelial carcinoma.
- Author
-
Mihai, Stan, Geavlete, P., Ene, C., and Geavlete, B.
- Subjects
TRANSITIONAL cell carcinoma ,ENDOSCOPIC surgery ,TECHNOLOGICAL innovations ,BLADDER cancer ,THERAPEUTICS ,TUMOR grading - Abstract
Introduction: Upper-tract urothelial carcinoma (UTUC) accounts for 5-10% of urothelial carcinomas. The 'gold standard' surgical treatment for UTUC is still represented by radical nephroureterectomy (RNU) with bladder cuff excision. The European Association of Urology guidelines recommend offering kidney-sparing surgery (KSS) as primary treatment option to patients with low-risk disease. Sometimes, there is a lack of certainty regarding the diagnosis and tratment strategy of UTUC despite all techniques available such as cystoscopy, urinary citology, and computed tomography urography (CTU) which do now always allow correct tumor staging and grading. Diagnostic ureteroscopy (d-URS) may be of crucial importance in establishing the appropriate therapeutic approach. Evidence acquisition: A systematic review of the literature using Pubmed electronic database was performed for studies evaluating the diagnostic modalities and tratment strategies in UTUC. Overall, 74 full-text articles were assessed for eligibility. After a quantitative review of the selected literature, 24 studies were considered relevant for this review. Results: CTU has a sensitivity and specificity for UTUC of 92% and 95% respectively, but is not able to detect small or flat lessions with adequate accuracy. Urine citology for UTUC has a sensitivity of around 67-76% and is considered to offer poor prediction of muscle-invasive or high-grade disease. As no technique offers a diagnosis certainty, diagnostic ureteroscopy with enhanced technical improvements and emerging technologies can allow an increase in diagnostic accuracy by distinguishing between normal tissue and low- and high-grade tumors. Conclusions: Endoscopic treatment of even large, multifocal, low grade upper urothelial carcinoma is feasible also depending on each comfort level of expertise, does not involve significant complications and has good short-term oncologic outcomes. Proper patient selection is the main key for a better outcome when treating UUTC endoscopically. A better appreciation of the diagnostic limitations may help with choosing the weapon wisely. Maybe the most important feature of all is that the patient needs to be willing to undergo a close follow up with repetead endoscopic evaluations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
46. Bilateral spontaneous ureteral stent fragmentation: a case report and literature review.
- Author
-
Catalin, Bulai, Geavlete, P., Georgescu, D., Ene, C., Militaru, A., Punga, A., and Geavlete, B.
- Subjects
SURGICAL stents ,LITERATURE reviews ,KIDNEY pelvis ,BLADDER ,URINALYSIS ,HYDRONEPHROSIS ,RETENTION of urine - Abstract
Ureteral stents are a fundamental element in the arsenal of urologists from their appearance until now. Due to the widespread usage of ureteral catheters, a number of possible complications such as migration, infection, encrustation, calcification, and fragmentation have been noted. In this manuscript, we present a case of a 70-year-old female patient who was admitted to the emergency room with bilateral flank pain for about 7 days and fragments of ureteral stent protruding through the urethra. The urine analysis showed leukocyturia, proteinuria, and microscopic hematuria. The X-ray highlighted multiple fragments of double J stent on the projection area kidneys and bladder. CT examination described atrophic kidneys with pelvic dilatation and ureteral catheter parts in both renal pelvis and bladder. Cystoscopy was performed under local anesthesia, residual ureteral stents fragments were removed from the bladder, and bilateral double J stents were placed for hydronephrosis remission. Bilateral double J stents were extracted after 3 weeks during a scheduled endoscopic procedure when the residual parts of double J were also evacuated by ureteroscopy from both kidneys. The postoperative evolution was favorable, simple. The particularity of the case is given by the fragmentation of the ureteral stents bilaterally in the same period of time. [ABSTRACT FROM AUTHOR]
- Published
- 2021
47. NBI cystoscopy in routine urological practice – from better vision to improve therapeutic management
- Author
-
Jecu, M., Geavlete, B., Mulţescu, R., Stănescu, F., Moldoveanu, C., Adou, L., Ene, C., Catalin Andrei Bulai, and Geavlete, P.
- Subjects
Male ,Special Article ,Narrow Band Imaging ,Urinary Bladder Neoplasms ,non-muscle invasive bladder tumors ,Urology ,Humans ,Female ,Cystoscopy ,standard cystoscopy ,monopolar transurethral resection ,Retrospective Studies - Abstract
Objectives: A single centre, retrospective trial was performed trying to assess the impact of NBI cystoscopy in cases of non-muscle invasive bladder tumors (NMIBT) by comparison to the standard approach. Our goal was to determine the superiority of the new method in terms of detection rates and subsequent postoperative treatment changes. Materials and Methods: A total of 320 NMIBT suspected consecutive cases were enrolled in the study. The inclusion criteria were represented by hematuria, positive urinary cytology and/or ultrasound suspicion of bladder tumors. All patients underwent WLC and NBI cystoscopy. Standard transurethral resection of bladder tumors (TURBT) was performed for all lesions visible in WL and NBI guided resection for solely NBI observed tumors. Results: The overall NMIBT and CIS patients’ detection rates were significantly improved for the NBI evaluation ((94.9% versus 88.1% and 95.7% versus 65.2%). Also, on a lesions’ related basis, NBI cystoscopy emphasized a significantly superior diagnostic accuracy concerning the CIS, pTa and overall NMIBT formations ((95.2% versus 60.3%, 92.8% versus 83.9% and 94.1% versus 82%). Additional tumors were diagnosed by NBI in a significantly higher proportion of CIS, pTa, pT1 and NMIBT patients (56.6% versus 8.7%, 28% versus 10.3%, 30.3% versus 10.6% and 31.6% versus 9.4%). As a result of these supplementary findings, the postoperative treatment was significantly improved in a substantial proportion of cases (15.4% versus 5.1%). Conclusions: NBI cystoscopy represents a valuable diagnostic alternative in NMIBT patients, with significant improvement of tumor visual accuracy as well as detection rates. This approach provided a substantial amelioration to the risk category stratification and subsequent bladder cancer therapeutic management.
- Published
- 2014
48. The impact of modern endourological techniques in the treatment of a century old disease - Medullary sponge kidney with associated nephrolithiasis
- Author
-
Geavlete, P, Nita, G, Alexandrescu, E, and Geavlete, B
- Subjects
Radiography ,Special Article ,medullary sponge kidney ,endourological techniques ,Humans ,Urologic Surgical Procedures ,Nephrolithiasis ,renal disorders ,Retrospective Studies - Abstract
The remarkable progresses of imagistic and interventional techniques that have been implemented during the last decades facilitated the diagnostic and allowed the treatment indication changes for numerous renal disorders. The purpose of the present lecture was to outline a data review concerning a renal anomaly first described one century ago as well as to evaluate the impact of endourologic technical progresses over the therapeutic management of the respective disease. The medullary sponge kidney (MSK) or Cacchi-Ricci disorder represents a disturbance in the renal development characterized by the cystic type dilation and diffuse precalyceal ducts ectasias. The disease is also known as precalyceal tubular ectasia, pyramidal sponge kidney or cystic dilation of the renal collecting ducts MSK patients are most often asymptomatic, the diagnosis being emphasized in light of the investigations imposed by related complications such as renal stones, urinary tract infections (pyelonephritis), renal tubes acidosis or urine concentration defects.
- Published
- 2013
49. Open surgical treatment in BPH - the experience over 10 years period of the Department of Urology, "St. John" Emergency Clinical Hospital, Bucharest, Romania.
- Author
-
Catalin, Bulai, Geavlete, P., Georgescu, D., Ene, C., Militaru, A., Punga, A., and Geavlete, B.
- Subjects
HOSPITAL emergency services ,BENIGN prostatic hyperplasia ,URINARY tract infections ,UROLOGY ,BLADDER stones - Abstract
Introduction. This study aimed to evaluate the experience of 10 years in the Department of Urology, "St. John" Emergency Clinical Hospital, Bucharest focusing on perioperative safety and morbidity but also on the evolution regarding the distribution of the number of interventions over time. Material and method. A total of 268 patients diagnosed with benign prostatic hyperplasia (BPH) who underwent suprapubic prostatectomy for a period of 10 years (January 2010 - December 2020) in the Department of Urology, "St. John" Emergency Clinical Hospital, Bucharest were included. The analyzed data was the age of the patients, the preoperatory symptoms, modifications in the bladder and prostate, and postoperative complications. Patients with malignant findings on histopathological examination were excluded. Results. The median age was 74 years. The most common symptoms at admission were frequency in 223 (83.2%), weak stream in 215 (80.2%) and dysuria in 213 (79.5%). The most common complications at presentation were urinary tract infection 79 (29.5%), acute urinary retention 45 (16.8%) and bladder stones 40 (14.9%). The average volume of the prostate measured by ultrasound was 121.2 cm3. The comorbid medical conditions were hypertension, diabetes, and Parkinson's disease. In all cases, a transvesical prostatectomy was performed. The following changes were observed during the surgery: thickened bladder wall in 145 patients (54.1%), trabeculations in 120 cases (44.7%), bladder diverticula in 58 patients (21.6%), bladder stones in 40 (14.9%) cases and 50 (18.6%) patients had prostate with a median lobe comparatively with 218 patients (81.3%) with overall prostate enlargement. Conclusions. Open prostate surgery is still required in the treatment plan for bulky prostate adenomas or in complications of BPH that indicate suprapubic prostatectomy at the expense of minimally invasive treatment methods. For superior results on operative safety and decreased risk of postoperative complications, patient comorbidities require careful management before surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
50. Ureteral duplication and upper urinary tract stones - there are differences in outcome?
- Author
-
Geavlete, B., Bragaru, M., Georgescu, D., and Geavlete, P.
- Subjects
URETEROSCOPY ,URINARY calculi ,URINARY organs ,RENAL colic ,KIDNEY stones ,URETERIC obstruction ,HUMAN abnormalities ,CONGENITAL disorders - Abstract
Introduction and Objectives. Collecting system duplication is one of the most common congenital anomalies of the urinary tract. Complete or incomplete duplication could be associated with ureteral or renal stones. Our objective was to compare urolithiasis treatment outcomes in patients with and without ureteral duplication. Material and methods. A total of 68 patients with ureteral duplication who underwent ureteroscopy (URS) for ureteral and renal stones were retrospectively evaluated from 1995 to 2019. We compared the outcome after ureteroscopy for 3 groups: Group 1 (47 patients with incomplete duplication), Group 2 (21 patients with complete duplication) and Group 3 (control group - 68 patients without ureteral anomalies). Pre- and postoperative data were analyzed. Stone location and size were perfect matched. Clinical data and outcomes were compared between the 3 groups. Results. For ureteral location (stones between 7-19 mm. diameters) there are differences concerning operative time (slightly longer for duplication cases): group 1 (19/47) average 36 min. (range 22 to 67 min.), group 2 (11/21) average 33 min. (range 19 to 71 min.) and group 3 (32/68) average 28 min. (range 20 to 48 min.). For renal location (stones between 9-28 mm. diameters) we found the same differences: group 1 (28/47) average 56 min. (range 27 to 81 min.), group 2 (10/21) average 49 min. (range 29 to 67 min.) and group 3 (36/68) average 39 min. (range 27 to 70 min.). Ureteral duplication had no effect on stone-free rates or need for additional procedures for ureteral stone location. For renal location we found a difference between Group 1 and 3 (68% stone-free for Group 1 vs. 79% for Group 3). Complication rate (Clavien1-3) was similar in all groups. We didn't describe any cases with Clavien 4 and 5. Also, the location of ureteral duplication did not affect operative time or stone-free rates. Conclusions. Ureteral duplication seems to have no significant effect on ureteroscopy safety and efficacy for upper urinary stones. We described a slightly longer operative time for duplication cases. The stone-free rate is significantly lower especially in incomplete duplication cases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.